Ustekinumab & Th17

Schematic representation of IL-12 and IL-23, and their receptors and downstream signaling pathways.
Cua and colleagues discuss the cellular and molecular rationale for targeting IL-12 and IL-23 for therapeutic purposes in inflammatory diseases; they also review existing clinical data, discuss potential side effects, and propose future directions for targeting these cytokines in additional disorder…

IL23 is an upstream cytokine in the Th17 axis, while IL12 is part of the Th1 immune response.
Immune diseases and Infections are seldom neatly partitioned into a specific T-helper dysfunction or response.

Ustekinumab, which targets both IL12 and IL23, may prove particularly useful in the treatment of certain diseases with considerable Th1-Th17 interplay.

The heterodimeric cytokines IL-12 and IL-23 play a key role in T helper cell and innate lymphocyte cell differentiation and expansion. They are composed of…

While IL17A inhibition with Secukinumab was found to be ineffective in Crohn’s Disease (possibly worsening it even), we are expectantly awaiting Ustekinumab’s positive phase 3 results.

Effective Therapy for Refractory Crohn’s Disease

This brief review covers a study that has reported on the effectiveness of ustekinumab in adults with moderate to severe Crohn’s disease resistant to anti-TNF treatment.

IL-23 Inhibitor Effective in Crohn’s Disease

Selective IL-23 inhibition has been touted to be the next great advance in the treatment of inflammatory bowel and psoriatic disease. The annual Digestive…

IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: Implications for therapy

Figure 1.

Hepatology Explore this journal > Explore this journal > Previous article in issue: Vascular cell adhesion molecule 1 expression by biliary epithelium promotes persistence of inflammation by inhibiting effector T-cell apoptosis Previous article in issue: Vascular cell adhesion molecule 1 expression…